Paris — French pharmaceuticals group Sanofi said on Wednesday it had suffered from low uptake for a new cholesterol drug and from concerns about a dengue vaccine but expressed confidence its pipeline of new products would support growth.

The world’s sixth-largest drug maker, which is battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said that it expected to file nine regulatory submissions in the next 18 months.

Some investors have voiced discontent with the group’s product pipeline and its failure to engage in a large acquisition since it appointed Olivier Brandicourt as CE in 2015.

Sanofi is under pressure to stand out in research and development as its diabetes division still has to overcome pricing constraints in the US, where its blockbuster insulin medication Lantus has lost its patent.

Brandicourt said at a company investor day that the group was "on track" to sell its European generic drugs unit in "the coming year", a long-awaited deal that could be worth more than €2bn, sources say.

"We are making good progress overall on our roadmap and I am confident that Sanofi now is much better positioned to deliver the sustained and long-term growth that our shareholders are expecting from us," he said.

The company said in November 2015 that its five-year strategic plan would result in six key launches, which were likely to generate peak sales of €12bn-€14bn by 2025.

One of them, Dengvaxia, is proving disappointing after findings the vaccine could, in some cases, increase the risk of severe dengue in recipients not previously infected by the virus. Once touted as a $1bn-a-year blockbuster, Dengvaxia’s initial sales in 2016 were only €55m.

Hurdles to patient access by health insurers and pharmacy benefit managers have also led to disappointing sales in Sanofi’s new cholesterol drug Praluent.

"When I turn to delivering outstanding launches I concede that our record over the past two years has been mixed," Brandicourt said. "While we are not changing our ambition of combined peak sales, we are clearly much more reliant on our immunology franchise."

In immunology, Sanofi has been focusing on "multitargeting" drugs that have the potential to treat more than one disease.

One example is dupilumab, which was developed with US partner Regeneron and for which it has secured approval in the US and Europe for eczema.

The drug is also expected to have uses in asthma, nasal polyps, eosinophilic esophagitis and food allergies. "Phase 3 development for dupilumab is now planned in chronic obstructive pulmonary disease," Sanofi said.

Sanofi, whose shares have underperformed major rivals, reiterated its strategy to rebuild its position in cancer treatment. It expected a first regulatory submission of its monoclonal antibody for relapsed refractory multiple myeloma in 2018.

The Cancer Research Institute said last week the race to develop new immunotherapy treatments for cancer had sparked an unprecedented expansion in the oncology drug pipeline, with more than 2,000 immune system boosters now in development.

The result is a scramble for patients to enrol in clinical trials, duplication of effort and probable failure of many projects, according to experts.


Please sign in or register to comment.